Immune Response to Percutaneous Hepatic Perfusion With Melphalan for Ocular Melanoma Metastatic to the Liver

Inclusion Criteria: * Patient has histologically or cytologically confirmed diagnosis of uveal melanoma metastatic to the liver and is determined to be a candidate for percutaneous hepatic perfusion with melphalan * The subject has read, signed and dated the Informed Consent Form (ICF), having been advised of the risks and benefits of the trial in a language understood by the subject. * Age \> 18 years at date of informed consent signature having the ability to comply with the protocol. * Contrast-enhanced cross-sectional imaging of the abdomen (either CT or MRI) obtained within two months prior to study enrollment * Measurable metastatic disease. Subject must have at least one site of metastatic disease ≥ 1 cm in size and amenable to percutaneous image-guided biopsy * Life expectancy \> 12 weeks. * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 * Laboratory requirements: * Absolute neutrophil count (ANC) \> 1 x 109/L * Platelets \> 75 x 109/L * Alanine aminotransferase (ALT) / Aspartate aminotransferase (AST) \< 5 x ULN * Total bilirubin \<3 mg/dL * International normalized ratio (INR) \<1.7 * Glomerular filtration rate (GFR) \>30 ml/min Exclusion Criteria: * Lesion to undergo biopsy cannot have undergone prior radiation therapy or other locoregional therapy * Continued adverse events from a previously administered chemotherapeutic agents. Grade 1 adverse events and ongoing toxicities such as alopecia are exempt * Treatment with systemic corticoste…